Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

dc.date.accessioned2021-12-12T20:24:56Z
dc.date.available2021-12-12T20:24:56Z
dc.date.created2021-12-12T20:24:56Z
dc.date.issued2021
dc.identifierhttps://hdl.handle.net/20.500.12866/10247
dc.identifierhttps://doi.org/10.1186/s13104-021-05832-0
dc.description.abstractObjective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru
dc.languageeng
dc.publisherBioMed Central
dc.relationBMC Research Notes
dc.relation1756-0500
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectDrug resistance
dc.subjectLevofloxacin
dc.subjectMoxifloxacin
dc.subjectOfloxacin
dc.titleFluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución